Current treatments for breast cancer focus on the killing malignant cells but there is a substantial population of patients for whom these approaches ultimately fail. The long-term objective of this work is to develop an adjuvant therapy that targets the tumor-promoting stroma of cancer as a way to potentiate current approaches. Tumor-associated macrophages (TAMs) are activated in the tumor microenvironment and facilitate disease progression by promoting angiogenesis and tumor cell growth, and by suppressing the adaptive immune response. We have recently identified a peptide that preferentially recognizes murine tumor-associated macrophage but not resting macrophage, other leukocytes, or tumor cells. In this work, we will prepare multivalent targeting constructs to deliver pro-apoptotic agents to TAMs in a mouse model of mammary cancer. In addition, we will develop analogous targeting peptides for human TAMs. These technologies will be combined in a new construct for targeted ablation of human TAMs. Our goal is to move this technology toward clinical development and to provide an adjuvant treatment that is effective even for women with hormone-unresponsive or triple negative breast cancer.

Public Health Relevance

There is a great need for alternative methods to treat chemotherapy-resistant breast cancer. The main goal of this proposal is to develop drug delivery technologies targeted to tumor-associated cells that protect cancers from recognition by the immune system and from chemotherapies. We expect that these materials will potentiate the action of chemotherapies to make them more effective for eradicating tumor cells.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Gene and Drug Delivery Systems Study Section (GDD)
Program Officer
Forry, Suzanne L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
Biomedical Engineering
Schools of Engineering
United States
Zip Code
Olden, Brynn R; Cheng, Yilong; Yu, Jonathan L et al. (2018) Cationic polymers for non-viral gene delivery to human T cells. J Control Release 282:140-147
Wang, Christine E; Yumul, Roma C; Lin, Jonathan et al. (2018) Junction opener protein increases nanoparticle accumulation in solid tumors. J Control Release 272:9-16
Peeler, David J; Thai, Salina N; Cheng, Yilong et al. (2018) pH-sensitive polymer micelles provide selective and potentiated lytic capacity to venom peptides for effective intracellular delivery. Biomaterials 192:235-244
Yen, Albert; Cheng, Yilong; Sylvestre, Meilyn et al. (2018) Serum Nuclease Susceptibility of mRNA Cargo in Condensed Polyplexes. Mol Pharm 15:2268-2276
Gustafson, Heather H; Olshefsky, Audrey; Sylvestre, Meilyn et al. (2018) Current state of in vivo panning technologies: Designing specificity and affinity into the future of drug targeting. Adv Drug Deliv Rev 130:39-49
Lee, Daniel C; Lamm, Robert J; Prossnitz, Alex N et al. (2018) Dual Polymerizations: Untapped Potential for Biomaterials. Adv Healthc Mater :e1800861
Butterfield, Gabriel L; Lajoie, Marc J; Gustafson, Heather H et al. (2017) Evolution of a designed protein assembly encapsulating its own RNA genome. Nature 552:415-420
Ngambenjawong, Chayanon; Pun, Suzie H (2017) Multivalent polymers displaying M2 macrophage-targeting peptides improve target binding avidity and serum stability. ACS Biomater Sci Eng 3:2050-2053
Ngambenjawong, Chayanon; Gustafson, Heather H; Sylvestre, Meilyn et al. (2017) A Facile Cyclization Method Improves Peptide Serum Stability and Confers Intrinsic Fluorescence. Chembiochem 18:2395-2398
Ngambenjawong, Chayanon; Gustafson, Heather H; Pun, Suzie H (2017) Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev 114:206-221

Showing the most recent 10 out of 23 publications